Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology

Authors: Weber DM, Stroh MA, Taylor SW, Lagier RJ, Louie JZ, Clarke NJ, Vaillancourt DE, Rayaprolu S, Duara R, Racke MK

Citation: Neurol Clin Pract. 2025;15:e200546. doi:10.1212/CPJ.0000000000200546

Specialties: Neurology

Download key summary

Related content

On-Demand Webinar
Biomarker Testing in Alzheimer’s Disease
Publication
EXPRESS: New Plasma LC-MS/MS Assays for the Quantitation of Beta-amyloid Peptides and Identification of Apolipoprotein E Proteoforms for Alzheimer’s Disease Risk Assessment
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
Conference Presentation
Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.